Australia markets open in 39 minutes

Alpha Teknova, Inc. (TKNO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
21.68-1.42 (-6.15%)
At close: 4:00PM EDT
21.68 0.00 (0.00%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.10
Open22.89
Bid17.70 x 1000
Ask25.40 x 1000
Day's range21.40 - 22.89
52-week range16.90 - 30.89
Volume47,925
Avg. volume125,529
Market cap607.298M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.67
Earnings date11 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.67
  • GlobeNewswire

    Teknova Reports Second Quarter 2021 Financial Results

    —$8.3 million in total revenue, up 38% year-over-year— —Strong cash position of $108.0 million supports investment in long-term growth strategy— HOLLISTER, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2021. “W

  • GlobeNewswire

    Teknova to Report Second Quarter 2021 Financial Results on August 11

    HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market. Teknova management will host a conference call and webcast at 4:30 p.m. ET

  • GlobeNewswire

    Teknova Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    HOLLISTER, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that on June 29, 2021, it closed its previously announced initial public offering of 6,900,000 shares of its common stock, at a price to the public of $16.00 per share. The closing included 900,000 shares sold